Key result
Direct LNA-PCR from blood lysate yields ~95% sensitivity for detecting homozygous SMN1 deletions.
Why the study?
Many molecular diagnostic methods for spinal muscular atrophy require DNA purification and complex workflows that increase turnaround time and cost.
Does a direct LNA-PCR assay from blood lysate accurately detect homozygous SMN1 deletions in individuals suspected of SMA compared to MLPA?
Observational (n=792)
No
Does a direct LNA-PCR assay from blood lysate accurately detect homozygous SMN1 deletions in individuals suspected of SMA compared to MLPA?
The direct LNA-PCR assay provides a rapid, reliable, and cost-effective method for detecting homozygous SMN1 deletions directly from blood samples without DNA purification, facilitating broader SMA molecular testing.
Answers are grounded in this paper and cite their sources.
May accelerate SMA diagnosis in limited settings; leaves open accuracy and utility pending prospective validation.
Spinal Muscular Atrophy (SMA) is an autosomal recessive disorder most often caused by homozygous deletion of exon 7 in the SMN1 gene. Early and reliable molecular diagnosis is essential for clinical management, genetic counseling, and implementation of emerging therapeutic interventions. However, many molecular diagnostic methods require DNA purification and complex laboratory workflows, which may increase turnaround time and cost. In this study, we aimed to develop a rapid and simplified molecular diagnostic assay based on direct locked nucleic acid polymerase chain reaction (LNA-PCR) for the detection of homozygous SMN1 deletions without the need for DNA purification. Peripheral blood samples were collected from 792 individuals, including 61 multiplex ligation-dependent probe amplification (MLPA) confirmed SMA patients, 45 MLPA validated healthy controls, 56 MLPA validated SMA carriers and 630 clinical controls comprising healthy individuals aged over 40 years with no SMA-related symptoms reported between September 2022 and January 2025. Direct real-time polymerase chain reaction was performed using locked nucleic acid–modified primers targeting the SMN1 gene and the β-actin gene as an internal control. Reactions were conducted in a total volume of 10 µL using 2.5 µL of blood lysate without DNA extraction. Amplification status was used to determine the presence or absence of homozygous SMN1 deletions. Amplification of the β-actin control gene was successfully achieved in all samples, indicating adequate reaction performance. Among the 60 patients with MLPA-confirmed homozygous SMN1 deletion, the direct LNA-PCR assay correctly identified 57, corresponding to a sensitivity of 95.00% (95% CI: 86.3–98.4%). No false-positive results were observed among the 102 MLPA-validated negative individuals (45 healthy controls, 56 carriers, and 1 compound heterozygous patient), yielding a specificity of 100% (95% CI: 96.5–100%), a PPV of 100% (95% CI: 93.7–100%), an NPV of 97.14% (95% CI: 92.1–99.1%), and an overall diagnostic accuracy of 98.15% (95% CI: 94.7–99.6%). The compound heterozygous patient was classified as SMN1 -positive, reflecting the known limitation of real time polymerase chain reaction based approaches in identifying sequence variants. Overall, the assay demonstrated high diagnostic accuracy and robust performance for detecting homozygous SMN1 deletions. The direct LNA-PCR assay enables rapid, reliable, and cost-effective detection of homozygous SMN1 deletions directly from blood samples without DNA purification. This simplified workflow may facilitate broader implementation of molecular testing for SMA in routine clinical laboratories and resource-limited settings.
No takes yet. Share an insight, caveat, or question.
Amuran et al. (2026) conducted an observational in Spinal Muscular Atrophy (n=792). Direct LNA-PCR assay vs. Multiplex ligation-dependent probe amplification (MLPA) was evaluated on Diagnostic accuracy for detecting homozygous SMN1 deletions (Sensitivity 95.00%, 95% CI 86.3-98.4). The direct LNA-PCR assay from blood lysate without DNA purification demonstrated 95.00% sensitivity and 100% specificity for detecting homozygous SMN1 deletions in spinal muscular atrophy.
Synapse has enriched 10 related papers. Consider them for comparative context: